Important Updated Safety Information - Effective 9/9/2008
Read the Medication Guide before you start Rituxan and before each Rituxan infusion

Targeted B-Cell Therapy

Rituxan® (Rituximab) is a unique therapy that selectively targets CD20-positive B-cells, shown to play an important role in non-Hodgkin's lymphoma and rheumatoid arthritis. Rituxan continues to redefine B-cell therapy with more than 10 years of clinical experience across all indications and more than 1,000,000 patient-exposures. Our journey continues.

Learn more about Rituxan for...

INDICATIONS AND USAGE

Non-Hodgkin's Lymphoma (NHL)

Rituxan® (rituximab) is indicated for the treatment of patients with:

  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
  • Non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens

Rheumatoid Arthritis

Rituxan® (rituximab) in combination with methotrexate is indicated to reduce signs and symptoms and to slow the progression of structural damage in adult patients with moderately-to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

BOXED WARNINGS and Additional Important Safety Information

The most important serious adverse reactions of Rituxan are fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation with fulminant hepatitis, other viral infections, cardiovascular events, renal toxicity, and bowel obstruction and perforation. The most common adverse reactions of Rituxan (incidence ≥25%) observed in patients with NHL are infusion reactions, fever, chills, infection, asthenia, and lymphopenia. The most common adverse reactions of Rituxan observed in patients with RA are hypertension, nausea, upper respiratory tract infection, arthralgia, pruritus, and pyrexia.

Attention healthcare provider: Provide Medication Guide to patient prior to Rituxan infusion.

For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.